Jeffrey Friedland at the Blavatnik Center for Drug Discovery at Tel Aviv University
Jeffrey Friedland, CEO
Jeffrey Friedland has been the chief executive officer and a director of a NASDAQ listed company, a director of a New York Stock Exchange-listed company, and the chairman of the supervisory board of a Hong Kong-based company listed on the Frankfurt Stock Exchange. Mr. Friedland has also been the CEO and a founder of a publicly-traded preclinical pharma research company.
Mr. Friedland is the CEO of US-based FC Global Strategies LLC, which provides advisory services and programs to companies in numerous industries.
He is also an inventor of a US patent for a method for treating the symptoms of myotonia comprising administering a therapeutically effective amount of cannabidiol (CBD) and tetrahydrocannabinol (THC) in a formulation that contains a ratio of CBD to THC in pharmaceutically-acceptable excipients.
He has been featured or quoted in numerous publications, including the Wall Street Journal, Reuters, the New York Times, Bloomberg Television, USA Today, Verslo Zinios (Lithuania), Vercernji (Croatia), International Business Times, the South China Morning Post, the Guam Daily Post, the Forward, the Jewish Week, Quartz, the Jakarta Globe, Israel Daily Television, Breitbart, NBC.com and Forbes.
Mr. Friedland has been a speaker or panelist at conferences and events throughout North America, Europe, the Middle East, and Asia.
Mr. Friedland is the author of two books, the most recent of which is Marijuana: The World's Most Misunderstood Plant, which is available in print and Kindle editions at Amazon.
As a staunch advocate of entrepreneurship, Mr. Friedland's focus has been on enabling entrepreneurs to achieve their dreams, whether they're a start-up, early-stage company or an established and growing company.